Previous Article | Next Article ![]()
J Virol, March 1998, p. 1894-1901, Vol. 72, No. 3
Systemix Inc., a Novartis Company, Palo Alto,
California 94304
Received 30 June 1997/Accepted 17 November 1997
The antiviral activities of intracellularly expressed antisense
RNAs complementary to the human immunodeficiency virus type 1 (HIV-1) pol, vif, and env genes and
the 3' long terminal repeat (LTR) sequence were
evaluated in this comparative study. Retroviral vectors
expressing the antisense RNAs as part of the Moloney murine leukemia virus LTR promoter-directed retroviral transcript were constructed. The CD4+ T-cell line CEM-SS was
transduced with retroviral constructs, and Northern blot analyses
showed high steady-state antisense RNA expression levels. The most
efficient inhibition of HIV-1 replication was observed with the
env antisense RNA, followed by the pol
complementary sequence, leading to 2- to 3-log10 reductions in p24 antigen production even at high inoculation doses (4 × 104 50% tissue culture infective doses) of the HIV-1
strain HXB3. The strong antiviral effect correlated with a reduction of
HIV-1 steady-state RNA levels, and with intracellular Tat protein
production, suggesting that antisense transcripts act at an early step
of HIV-1 replication. A lower steady-state antisense RNA
level was detected in transduced primary CD4+ lymphocytes
than in CEM-SS cells. Nevertheless, replication of the HIV-1 JR-CSF
isolate was reduced with both the pol and env antisense RNA. Intracellularly expressed antisense sequences
demonstrated more pronounced antiviral efficacy than the
trans-dominant RevM10 protein, making these antisense
RNAs a promising gene therapy strategy for HIV-1.
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Comparative Analyses of Intracellularly Expressed
Antisense RNAs as Inhibitors of Human Immunodeficiency Virus Type
1 Replication


*
Corresponding author. Mailing address: Systemix Inc.,
3155 Porter Dr., Palo Alto, CA 94304. Phone: (415) 813-5040. Fax: (415) 813-5101. E-mail: gveres{at}stem.com.
Present address: Novartis Pharmaceuticals, Basel, Switzerland.
Present address: Rhône-Poulenc Rorer, 94403 Vitry-sur-Seine,
France.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»